Recommendations for the use of off-label rituximab for the treatment of multiple sclerosis in low-resource settings

Post time 5 day(s) ago

journal：Multiple Sclerosis and Related Disorders

Authors：Nick Rijke; Bassem I Yamout; Deanna Saylor; Francesco Nonino; Graziella Filippini; Thomas Piggott; Joanna Laurson-Doube; Laura Amato; Tapas K Banerjee; Kathleen Costello; Cinzia Del Giovane; Nicola De Stefano; Najoua El Abkari; Gavin Giovannoni; Hans-Peter Hartung; Anne Helme; Aukje Mantel-Teeuwisse; Andrea Prato Chichiraldi; Mohammad Ali Sahraian; Fatima Suleman; Simona Vecchi; Maya Zeineddine; Shanthi Viswanathan; Holger Schünemann

Published date：2026-1-

DOI：10.1016/j.msard.2025.106878

PDF link：https://www.sciencedirect.com/sc ... 211034825006200/pdf

Article link：https://doi.org/10.1016/j.msard.2025.106878

Article Source：Elsevier BV。

Remark：

Post time 5 day(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Elsevier] Recommendations for the use of off-label rituximab for the treatment of multiple sclerosis in low-resource settings

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] Recommendations for the use of off-label rituximab for the treatment of multiple sclerosis in low-resource settings Copy

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] Recommendations for the use of off-label rituximab for the treatment of multiple sclerosis in low-resource settings